On May 1, the US Food and Drug Administration announced the emergency use authorization to remdesivir, an experimental antiviral drug. This gap is now to use doctors in the US to make the drug to patients dealing with severe cases of COVID-19 allowed. Remdesivir is not new. It was originally developed hepatitis C and RSV for the treatment of a virus that causes respiratory infections. It ‘been investigated other coronaviruses as a treatment for Ebola and SARS and two-Mers that infect humans similar to the virus that causes COVID-19 That never made it to the stage of approval for these applications, but desperately in the last four months , scientists looked for ways around the crown mitigate older drugs in the event of a pandemic which could be repurposed. Remdesivir during this period has traveled an unprecedented path to regulatory approval for one of the most promising treatments for COVID-19 to date. Remdesivir is no vaccine, and therefore can not prevent infection; Instead, it works by attacking the virus, if it spreads to the body. Here’s a look at how the virus spreads COVID-19 in the human body, and how it slows this process. Step 1: the virus does not replicate in a cell without the virus of a cell protein machinery is used. They must first gain entry into a healthy cell. Coronavirus, such as that caused COVID-19, have a shell of their sharp to allow proteins to bind cells. STEP 2: Virus versions of the genetic code, the virus fuses with the cell and, once inside, a print-stranded RNA. As a plan, the RNA is a series of genetic code, copies exact instructions to do the virus. STEP 3: genetic code converted to particles sensitive proteins in the host cell, the so-called ribosomes, equipped genetic material are to be read. When the RNA of the virus is through the ribosome, the ribosome produces viral proteins. Step 4: The proteins viral proteins copies are needed in order to make copies of viral RNA, as well as other parts of the virus, such as the outer tips and membrane. As more proteins and RNA strands are made, they multiply exponentially to make multiple copies that fills the cell. Step 5: Viral Viral parts parties use mechanisms in the host cell obtained to join together to form a complete virus. When fully assembled, the virus may leave the cell to search for other healthy cells and begin the process all over again. Step 6: Remdesivir Remdesivir replication blocks mimics a portion of the viral RNA. During the copying process, it is part of the RNA strand. When connected, the drug prevents further copying, stranded RNA to produce incomplete and do not leave it in place of critical organs virus. STEP 7: Virus slowed by drugs disabled, the entire replication process slows down. This means a smaller number of viruses are assembled. defective viruses with partial RNA can not replicate in other cells. Correction, May 27 The original version of this misrepresentation remdesivir original purpose history. E ‘was developed hepatitis C and RSV, do not treat Ebola.